

MEDICAL POLICY – 8.01.11

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies


BCBSA Ref. Policy: 8.01.11

Effective Date: Oct. 1, 2024
Last Revised: Sept. 23, 2024
Replaces: 8.01.505

RELATED MEDICAL POLICIES:
7.01.95 Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors
7.01.133 Microwave Tumor Ablation
8.01.521 Radioembolization for Primary and Metastatic Tumors of the Liver

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

Introduction

Embolization is a procedure to block blood flow. When the material used to block the blood flow contains chemotherapy agents as well, it is a way to treat liver cancer in some situations. This treatment is usually known as Transcatheter Arterial Chemoembolization (TACE). In this procedure a catheter (a long, thin, hollow tube) is inserted in an artery near the groin. It's threaded to the tumor's blood supply. Chemotherapy and tiny particles are then sent directly into the tumor. The particles block off — embolize — the artery feeding the tumor, causing it to shrink. The chemotherapy works to kill the cancer cells. This treatment can be used in the liver because it has two sources of blood: the portal vein and the hepatic artery. The portal vein supplies most of the blood to the liver. The hepatic artery supplies a lesser amount, and tumors that grow in the liver usually get their blood supply from the hepatic artery. As a result, TACE can be used to starve the blood supply of the tumor usually without affecting the blood supply to the rest of the liver. This policy describes when TACE may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Treatment	Medical Necessity
<p>Transcatheter hepatic arterial chemoembolization</p>	<p>Transcatheter hepatic arterial chemoembolization may be considered medically necessary in the following conditions:</p> <ul style="list-style-type: none"> • Hepatocellular cancer that is unresectable but confined to the liver and not associated with portal vein thrombosis and liver function is not characterized as Child-Pugh class C* • As a bridge to transplant in individuals with hepatocellular cancer where the intent is to prevent further tumor growth and to maintain an individual's candidacy for liver transplant, and the following is present: <ul style="list-style-type: none"> ○ A single tumor less than 5 cm or no more than 3 tumors each less than 3 cm in size ○ Absence of extrahepatic disease or vascular invasion ○ Child-Pugh class A or B* • Treat liver metastasis in symptomatic individuals with metastatic neuroendocrine tumor with both of the following: <ul style="list-style-type: none"> ○ Symptoms persist despite systemic therapy <p>AND</p> <ul style="list-style-type: none"> ○ Individuals are not candidates for surgical resection • To treat liver metastasis in individuals with liver-dominant metastatic uveal melanoma <p>Note: *See Related Information for Child-Pugh Classification</p>

Treatment	Investigational
<p>Transcatheter hepatic arterial chemoembolization</p>	<p>Transcatheter hepatic arterial chemoembolization is considered investigational in the following conditions:</p> <ul style="list-style-type: none"> • As neoadjuvant or adjuvant therapy in hepatocellular cancer that is considered resectable • When used in combination with radiofrequency ablation (RFA) to treat resectable or unresectable hepatocellular carcinoma



Treatment	Investigational
	<ul style="list-style-type: none"> To treat unresectable cholangiocarcinoma To treat liver metastases from any other tumors or to treat hepatocellular cancer that does not meet the criteria noted above, including recurrent hepatocellular carcinoma To treat hepatocellular tumors prior to liver transplantation except as noted above

Documentation Requirements

The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:

- Office visit notes that contain the relevant history and physical of ANY these situations:
 - The individual has primary liver cancer that cannot be surgically removed, located only in the liver and does not involve clot or narrowing of the portal vein
 - As a short-term treatment for an individual with primary liver cancer waiting for a liver transplant, and the following are true
 - A single tumor less than 5 cm or no more than 3 tumors each less than 3 cm in size
 - Absence of extrahepatic disease or vascular invasion
 - Child-Pugh class A or B
 - The individual has tumors from neuroendocrine cancer that have spread to the liver when the tumors can't be removed surgically and have not responded to other therapy
 - The individual has tumors in the liver that have spread from liver-dominant metastatic uveal melanoma

Coding

Code	Description
CPT	
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction
75894	Transcatheter therapy, embolization, any method, radiological supervision and interpretation

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).



Related Information

Child-Pugh Classification of Liver Disease

Parameter	Points assigned		
	1	2	3
Ascites	None	Suppressed with meds	Refractory
Bilirubin	< 34 µM	34 - 50 µM	> 50 µM
Albumin	> 35 g/L	28 – 35 g/L	< 28 g/L
INR	< 1.7	1.7 – 2.2	> 2.2
Encephalopathy	Grade 0	Grade 1 – 2 or suppressed with meds	Grade 3 – 4 or refractory
-Grade 0: normal cognition -Grade 1: euphoria, fluctuation in level of consciousness, slurred/disoriented speech -Grade 2: drowsiness, inappropriate behavior, loss of sphincteric control -Grade 3: marked confusion, stupor, incoherent speech -Grade 4: coma			
Class A	5 – 6 points	"well-compensated"	
Class B	7 – 9 points	"significant functional impairment"	
Class C	10 – 15 points	"decompensated liver function"	

Source: <http://www.bccancer.bc.ca/books/PublishingImages/Gastrointestinal/Child-Turcotte-Pugh.PNG>

Accessed August 16, 2024.

Evidence Review

Description

Transcatheter arterial chemoembolization (TACE) of the liver is a proposed alternative to conventional systemic or intra-arterial chemotherapy and to various nonsurgical ablative techniques, to treat resectable and nonresectable tumors. TACE combines the infusion of chemotherapeutic drugs with particle embolization. Tumor ischemia secondary to the embolization raises the drug concentration compared with infusion alone, extending the



retention of the chemotherapeutic agent and decreasing systemic toxicity. The liver is especially amenable to such an approach, given its distinct lobular anatomy, the existence of two independent blood supplies, and the ability of healthy hepatic tissue to grow and thus compensate for tissue mass lost during chemoembolization.

Background

Transcatheter Arterial Chemoembolization

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed by interventional radiologists who inject highly concentrated doses of chemotherapeutic agents into the tumor tissues and embolic agent(s) to restrict tumor blood supply. The embolic agent(s) causes ischemia and necrosis of the tumor and slows anticancer drug washout. The most common anticancer drugs used in published TACE studies for hepatocellular carcinoma (HCC) include doxorubicin (36%), followed by cisplatin (31%), epirubicin (12%), mitoxantrone (8%), and mitomycin C (8%).¹

The TACE procedure requires hospitalization for placement of a hepatic artery catheter and workup to establish eligibility for chemoembolization. Before the procedure, the patency of the portal vein must be demonstrated to ensure an adequate posttreatment hepatic blood supply. With the individual under local anesthesia and mild sedation, a superselective catheter is inserted via the femoral artery and threaded into the hepatic artery. Angiography is then performed to delineate the hepatic vasculature, followed by injection of the embolic chemotherapy mixture. Embolic material varies but may include a viscous collagen agent, polyvinyl alcohol particles, or ethiodized oil. Typically, only one lobe of the liver is treated during a single session, with subsequent embolization procedures scheduled five days to six weeks later. In addition, because the embolized vessel recanalizes, chemoembolization can be repeated as many times as necessary.

Adverse Events

TACE of the liver has been associated with potentially life-threatening toxicities and complications, including severe postembolization syndrome, hepatic insufficiency, abscess, or infarction. TACE has been investigated to treat resectable, unresectable, and recurrent hepatocellular carcinoma, cholangiocarcinoma, liver metastases, and in the liver transplant setting. Treatment alternatives include resection when possible, other locally ablative techniques (e.g., radiofrequency ablation, cryoablation) and chemotherapy administered systemically or by



hepatic artery infusion. Hepatic artery infusion involves the continuous infusion of chemotherapy with an implanted pump, while TACE is administered episodically. Hepatic artery infusion does not involve the use of embolic material.

Summary of Evidence

Unresectable and Resectable Hepatocellular Carcinoma

For individuals who have unresectable hepatocellular carcinoma (HCC) confined to the liver and not associated with portal vein thrombosis who receive TACE, the evidence includes several randomized controlled trials (RCTs), large observational studies, and systematic reviews. The relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. Evidence from one RCT has suggested that survival with TACE is at least as good as with systemic chemotherapy. One systematic review has highlighted possible biases associated with RCTs that compared TACE with no therapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have resectable HCC who receive neoadjuvant or adjuvant TACE, the evidence includes several RCTs and systematic reviews. The relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. Studies have shown little to no difference in overall survival rates with neoadjuvant TACE compared with surgery alone. A meta-analysis found no significant improvements in survival or recurrence with preoperative TACE for resectable HCC. While both RCTs and the meta-analyses that evaluated TACE as adjuvant therapy to hepatic resection in HCC reported positive results, the quality of individual studies and the methodologic issues related to the meta-analyses preclude certainty when interpreting the results. Well-conducted multicentric trials from the US or Europe representing relevant populations with adequate randomization procedures, blinded assessments, centralized oversight and publication in peer-reviewed journals are required. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have resectable HCC who receive TACE plus radiofrequency ablation (RFA), the evidence includes a single RCT and a systematic review. The relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. The RCT failed to show the superiority in survival benefit with combination TACE plus RFA treatment compared with surgery for HCC lesions 3 cm or smaller. Further, an ad hoc subgroup analysis showed a significant benefit for surgery in recurrence and overall survival in individuals with lesions larger than 3 cm. It cannot be determined from this trial whether TACE plus RFA is



as effective as surgical resection for these small tumors. The systematic review, which included mostly retrospective observational studies, did not find a survival benefit with TACE plus RFA over surgery alone. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unresectable HCC who receive TACE plus RFA, the evidence includes multiple systematic reviews and RCTs. The relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. Multiple meta-analyses and RCTs have shown a consistent benefit in survival and recurrence-free survival favoring combination TACE plus RFA over RFA alone. However, results of these meta-analyses are difficult to interpret because the pooled data included heterogeneous individual populations and, in a few cases, data from a study retracted due to questions about data veracity. A larger well-conducted RCT has reported a relative reduction in the hazard of death by 44% and a 14% difference in 4-year survival favoring combination therapy. The major limitations of this trial were its lack of a TACE-alone arm and the generalizability of its findings to individual populations that have unmet needs such as those with multiple lesions larger than 3 cm and Child-Pugh class B or C. Further, this single-center trial was conducted in China, and until these results have been reproduced in individual populations representative of pathophysiology and clinical stage more commonly found in the US or Europe, the results may not be generalizable. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Bridge to Liver Transplant

For individuals who have a single hepatocellular tumor less than 5 cm or no more than three tumors each less than 3 cm in size, absence of extrahepatic disease or vascular invasion, and Child-Pugh class A or B seeking to prevent further tumor growth and to maintain candidacy for liver transplant who receive pretransplant TACE, the evidence includes multiple small prospective studies. The relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. There is a lack of comparative trials on various locoregional treatments as a bridge therapy for liver transplantation. Multiple small prospective studies have demonstrated that TACE can prevent dropouts from the transplant list. TACE has become an accepted method to prevent tumor growth and progression while individuals are on the liver transplant waiting list. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.



Unresectable Intrahepatic Cholangiocarcinoma

For individuals who have unresectable intrahepatic cholangiocarcinoma who receive TACE, the evidence includes several retrospective observational studies and systematic reviews. Relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. RCTs evaluating the benefit of adding TACE to the standard of care for individuals with unresectable intrahepatic cholangiocarcinoma are lacking. Results of retrospective studies (noncontrolled) have shown a survival benefit with TACE over the standard of care; however, systematic reviews comparing TACE to other locoregional therapies are conflicting. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

TACE for Symptomatic Unresectable Neuroendocrine Tumors

For individuals who have symptomatic metastatic neuroendocrine tumors despite systemic therapy and are not candidates for surgical resection who receive TACE, the evidence includes retrospective single-cohort studies. Relevant outcomes are overall survival, disease-specific survival, symptoms, quality of life, and treatment-related mortality and morbidity. There is a lack of evidence from RCTs supporting the use of TACE. Uncontrolled trials have suggested that TACE reduces symptoms and tumor burden and improves hormone profiles. Generally, the response rates are over 50% and include individuals with massive hepatic tumor burden. While many studies have demonstrated symptom control, survival benefits are less clear. Despite the uncertain benefit on survival, the use of TACE to palliate the symptoms associated with hepatic neuroendocrine metastases can provide a clinically meaningful improvement in net health outcome. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Liver-Dominant Metastatic Uveal Melanoma

For individuals who have liver-dominant metastatic uveal melanoma who receive TACE, the evidence includes observational studies and reviews. Relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. There is a lack of evidence from RCTs assessing use of TACE. Noncomparative prospective and retrospective studies have reported improvements in tumor response and survival compared with historical controls. Given the very limited treatment response from systemic therapy and the rarity of this condition, the existing evidence may support conclusions that TACE



meaningfully improves outcomes for individuals with hepatic metastases from uveal melanoma. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Other Unresectable Hepatic Metastases

For individuals who have unresectable hepatic metastases from any other types of primary tumors (e.g., colorectal or breast cancer) who receive TACE, the evidence includes multiple RCTs, observational studies, and systematic reviews. The relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. Multiple RCTs and numerous nonrandomized studies have compared TACE with alternatives in individuals who have colorectal cancer with metastases to the liver. Nonrandomized studies have reported that TACE can stabilize disease in 40% to 60% of treated individuals but whether this translates into a prolonged survival benefit relative to systemic chemotherapy alone is uncertain. Two small RCTs have reported that TACE with drug-eluting beads has resulted in statistically significant improvements in response rate and progression-free survival. Whether this translates into a prolonged survival benefit relative to systemic chemotherapy alone is uncertain. For cancers other than colorectal, the evidence is extremely limited, and no conclusions can be made. Studies have assessed small numbers of individuals and the results have varied due to differences in individual selection criteria and treatment regimens used. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in [Table 1](#).

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT06353126	A Prospective, Single Arm, Exploratory Study of Using Drug-eluting Beads Transarterial Chemoembolization Prior	40	Jul 2027



NCT No.	Trial Name	Planned Enrollment	Completion Date
	to SALT Liver Transplantation in the Treatment of Hepatocellular Carcinoma		
NCT03960008	A Randomized Multi-Center Phase III Study of Individualized Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as a Bridge to Transplant (SBRTvsTACE) in Hepatocellular Carcinoma	196	Mar 2024
NCT04143191	Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC (SOURCE). A Phase III, Multicenter, RCT	158	Sep 2023 (unknown status)
NCT04912258	Trans-arterial Chemoembolization With Irinotecan Drug-eluting Beads Before Liver Surgery for Patients With Primary Unresectable Colorectal Liver Metastasis: A Randomized Control Trial	80	Jun 2023 (unknown status)
NCT02724540^a	Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver	162	Sept 2024
Unpublished			
NCT02936388	A Randomized Phase II Trial of Transarterial Radioembolisation with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma	108	Dec 2022 (unknown status)

NCT: national clinical trial. ^a Denotes an industry sponsored or cosponsored clinical trial.

Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2012 Input

In response to requests, input was received from one specialty medical society (two reviewers) and three academic medical centers while this policy was under review in 2012. There was general agreement that the use of TACE was medically necessary for indications in the policy;



however, reviewers were split for its use as a bridge to transplant. There was general support for the investigational policy statement for the use of TACE as neoadjuvant or adjuvant therapy in resectable HCC. Reviewers were split over the investigational policy statement to treat other liver metastases or for recurrent HCC. Four reviewers provided input on the use of TACE in unresectable cholangiocarcinoma; two reviewers considered it investigational and two others considered it investigational but also medically necessary, the latter citing data showing a survival benefit of TACE compared with supportive therapy.

Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network Guidelines

Hepatocellular Carcinoma

The National Comprehensive Cancer Network (NCCN) (v. 1.2024) guidelines on hepatocellular carcinoma list TACE as an option for individuals who are not candidates for surgically curative treatments or as a part of a strategy to bridge individuals for other curative therapies.¹¹⁷ Arterially directed therapies, including TACE, are appropriate for individuals with unresectable or inoperable tumors that are not amenable to ablation therapy. Additionally, TACE in highly selected individuals has been shown to be safe in the presence of limited tumor invasion of the portal vein. The American Association for the Study of Liver Diseases 2023 guidelines on hepatocellular carcinoma state that patients with Barcelona Clinic Liver Cancer Stage B HCC should receive TACE (Level 1, strong recommendation).¹¹⁸ Both conventional TACE and drug-eluting bead TACE are mentioned, with no preference noted between these 2 modalities. The guideline also suggests using neoadjuvant locoregional therapies (which may include TACE) for bridging to liver transplant in patients with T2 lesions, in order to prevent disease progression and prevent dropouts from the waiting list. The guidelines recommend the use of locoregional therapies, including TACE, in individuals with cirrhosis and T2 or T3 disease that is not amenable



to resection or transplantation. The American Society of Clinical Oncology (ASCO) 2024 guideline on advanced HCC states that patients with locally advanced disease may be candidates for liver-directed therapies (including TACE); however, the guideline is focused on systemic therapy so there are no recommendations regarding TACE.¹¹⁹

Intrahepatic Cholangiocarcinoma

The NCCN (v. 2.2024) guidelines on biliary tract cancers including intrahepatic cholangiocarcinoma consider arterially directed therapies, including TACE, to be treatment options for unresectable and metastatic intrahepatic cholangiocarcinoma.¹¹⁷

Neuroendocrine Tumors and Adrenal Tumors

The NCCN (v.1.2023) guidelines on neuroendocrine and adrenal tumors recommend hepatic regional therapy, including arterial embolization, chemoembolization, or radioembolization, for unresectable liver metastases (category 2B).¹²⁰

Uveal Melanoma Cancer

The NCCN (v.1.2023) guidelines on uveal melanoma state that in individuals with disease that is confined to the liver, regional liver-directed therapies such as chemoembolization, radioembolization, or immunoembolization should be considered.¹²¹

Colon Cancer

The NCCN (v. 2.2024) guidelines on colon cancer recommend TACE only for clinical trials.¹²² The American Society of Clinical Oncology (ASCO, 2020) resource-stratified guidelines on late-stage colorectal cancer state that individuals with unresectable liver metastases may receive TACE (weak recommendation).¹²³ However, this recommendation should only be implemented in centers with expertise in the technique, after multidisciplinary review, or in the context of a clinical trial. The 2022 guidelines for metastatic colorectal cancer from ASCO do not address TACE.¹²⁴



Breast Cancer

The NCCN (v. 4.2024) guidelines on breast cancer do not address TACE as a treatment option for breast cancer metastatic to the liver.¹²⁵

Medicare National Coverage

There is no national coverage determination.

Regulatory Status

Chemoembolization for hepatic tumors is a medical procedure and, as such, is not subject to regulation by the US Food and Drug Administration. However, the embolizing agents and drugs are subject to US Food and Drug Administration approval.

References

1. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. *Cardiovasc Intervent Radiol*. 2007; 30(1): 6-25. PMID 17103105
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcatheter arterial chemoembolization of hepatic tumors. TEC Assessments. 2000;Volume 15;Tab 22.
3. National Cancer Institute, Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. 2024; <https://seer.cancer.gov/statfacts/html/livibd.html>. Accessed August 16, 2024.
4. Qi X, Wang D, Su C, et al. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. *Oncotarget*. Jul 30 2015; 6(21): 18715-33. PMID 26243835
5. Tian X, Dai Y, Wang DQ, et al. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. *Drug Des Devel Ther*. 2015; 9: 4431-40. PMID 26309396
6. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. *Cochrane Database Syst Rev*. Mar 16 2011; (3): CD004787. PMID 21412886
7. Xie F, Zang J, Guo X, et al. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. *J Cancer Res Clin Oncol*. Mar 2012; 138(3): 455-62. PMID 22179199
8. Ahmad J, Rhee J, Carr BI. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma. *Dig Dis Sci*. Feb 2005; 50(2): 331-5. PMID 15745096
9. Akamatsu M, Yoshida H, Obi S, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. *Liver Int*. Dec 2004; 24(6): 625-9. PMID 15566514



10. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology*. Jun 1998; 27(6): 1578-83. PMID 9620330
11. Cao GW, Hu S, Li G, et al. The clinical and experimental research of transhepatic arterial injection of 32P-glass microsphere therapy for hepatic carcinoma. *J Med Imaging*. 2005;15(8):678681.
12. Cao XC, Wang X, Tan J, et al. Clinical research of intra-arterial radioembolization with 32P-glass microspheres combined with chemoembolization for treatment of liver cancer. *Chin J Radiol*. 2005;39(10):10681072.
13. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. *Cancer*. Mar 01 2010; 116(5): 1305-14. PMID 20066715
14. Cheng SQ, Wu MC, Chen H, et al. [Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma]. *Zhonghua Zhong Liu Za Zhi*. May 2004; 26(5): 305-7. PMID 15312371
15. Doffoël M, Bonnetain F, Bouché O, et al. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). *Eur J Cancer*. Mar 2008; 44(4): 528-38. PMID 18242076
16. Du W, Lin S, Luo K, et al. Clinical analysis of TACE plus 32P-GMS in advanced hepatic carcinoma. *J Hepatobilia Surg*. 2002;10(5):351352.
17. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. *N Engl J Med*. May 11 1995; 332(19): 1256-61. PMID 7708069
18. Hao N, Xiao X, Han X, et al. Efficacy of intra-arterial chemoembolization using drug microspheres in compare with chemoembolization in the treatment of primary hepatic carcinoma. *Tumor (Shanghai)*. 2000;20(5):375378.
19. Hou P, Guan G, Zhang X, Lu H, Wang S. Effects of intra-advanced 32P glass microspheres for advanced hepatic carcinoma. *Academic Journal of Fujian Medical University*. 2006;40(1):4850.
20. Kirchoff TD, Rudolph KL, Layer G, et al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. *Eur J Surg Oncol*. Mar 2006; 32(2): 201-7. PMID 16373084
21. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. *J Vasc Interv Radiol*. Feb 2010; 21(2): 224-30. PMID 20022765
22. Lee W, Luo J, Yan Z, et al. Hepatic radioembolization with epirubicin mixed microsphere for the treatment of hepatocellular carcinoma. *J Nantong Univ (Medical Sciences)*. 2008;28(4):268270.
23. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant*. Aug 2009; 9(8): 1920-8. PMID 19552767
24. Li JQ, Zhang YQ, Zhang WZ, et al. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. *J Cancer Res Clin Oncol*. 1995; 121(6): 364-6. PMID 7541051
25. Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. *Dig Surg*. 2006; 23(4): 235-40. PMID 16943671
26. Liu T, Zu M. Treatment of primary hepatic carcinoma by hepatic arterial chemoembolization with KMG microspheres and chemotherapeutic agents. *Acad Med Xuzhou*. 2005;25(2):126129.
27. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet*. May 18 2002; 359(9319): 1734-9. PMID 12049862
28. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology*. May 2002; 35(5): 1164-71. PMID 11981766



29. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. *J Hepatol.* Sep 1990; 11(2): 181-4. PMID 2174933
30. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. *J Hepatol.* Jul 1998; 29(1): 129-34. PMID 9696501
31. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology.* Feb 2011; 140(2): 497-507.e2. PMID 21044630
32. Xiao E, Li D, Shen S, et al. Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells. *Chin Med J (Engl).* Feb 2003; 116(2): 203-7. PMID 12775230
33. Bush DA, Smith JC, Slater JD, et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. *Int J Radiat Oncol Biol Phys.* May 01 2016; 95(1): 477-482. PMID 27084661
34. Mabed M, Esmaeel M, El-Khodary T, et al. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. *Eur J Cancer Care (Engl).* Sep 2009; 18(5): 492-9. PMID 19453695
35. Shen PC, Chang WC, Lo CH, et al. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. *Int J Radiat Oncol Biol Phys.* Oct 01 2019; 105(2): 307-318. PMID 31175903
36. Biederman DM, Titano JJ, Korff RA, et al. Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. *J Vasc Interv Radiol.* Jan 2018; 29(1): 30-37.e2. PMID 29169782
37. Molinari M, Kachura JR, Dixon E, et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. *Clin Oncol (R Coll Radiol).* Nov 2006; 18(9): 684-92. PMID 17100154
38. Takayasu K, Aarii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology.* Aug 2006; 131(2): 461-9. PMID 16890600
39. Biselli M, Andreone P, Gramenzi A, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. *Clin Gastroenterol Hepatol.* Sep 2005; 3(9): 918-25. PMID 16234031
40. Chan KS, Tay WX, Cheo FY, et al. Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥ 5 cm): a systematic review and meta-analysis. *Acta Chir Belg.* Dec 2023; 123(6): 601-617. PMID 37681991
41. Si T, Chen Y, Ma D, et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. *Scand J Gastroenterol.* Dec 2016; 51(12): 1512-1519. PMID 27598831
42. Zhou Y, Zhang X, Wu L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. *BMC Gastroenterol.* Mar 19 2013; 13: 51. PMID 23509884
43. Chua TC, Liauw W, Saxena A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. *Liver Int.* Feb 2010; 30(2): 166-74. PMID 19912531
44. Kaibori M, Tanigawa N, Kariya S, et al. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. *Dig Dis Sci.* May 2012; 57(5): 1404-12. PMID 22271410
45. Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. *Ann Surg.* Feb 2009; 249(2): 195-202. PMID 19212170
46. Cui H, Gao QQ, Li YY, et al. Influence of preventive effects of transcatheter arterial chemoembolization on primary hepatocellular carcinoma. *J Med Forum.* 2003;24:13.



47. Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. *Jpn J Cancer Res.* Feb 1996; 87(2): 206-11. PMID 8609071
48. Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. *Br J Surg.* Jan 1995; 82(1): 122-6. PMID 7881929
49. Yeh ML, Huang CI, Huang CF, et al. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. *Kaohsiung J Med Sci.* Feb 2015; 31(2): 77-82. PMID 25645985
50. Choi GH, Kim DH, Kang CM, et al. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?. *World J Surg.* Dec 2007; 31(12): 2370-7. PMID 17912587
51. Liang L, Li C, Diao YK, et al. Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis. *Therap Adv Gastroenterol.* 2020; 13: 1756284820977693. PMID 33329759
52. Liao M, Zhu Z, Wang H, et al. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. *Scand J Gastroenterol.* 2017; 52(6-7): 624-634. PMID 28276833
53. Li Q, Wang J, Sun Y, et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis--a randomized study. *World J Surg.* Nov 2006; 30(11): 2004-11; discussion 2012-3. PMID 17058027
54. Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. *J Cancer Res Clin Oncol.* Oct 2009; 135(10): 1437-45. PMID 19408012
55. Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. *Am J Surg.* Sep 2009; 198(3): 313-8. PMID 19285298
56. Gui CH, Baey S, D'cruz RT, et al. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. *Eur J Surg Oncol.* May 2020; 46(5): 763-771. PMID 31937433
57. Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. *Br J Surg.* Mar 2016; 103(4): 348-56. PMID 26780107
58. Ako S, Nakamura S, Nouse K, et al. Transcatheter Arterial Chemoembolization to Reduce Size of Hepatocellular Carcinoma before Radiofrequency Ablation. *Acta Med Okayama.* Feb 2018; 72(1): 47-52. PMID 29463938
59. Haochen W, Jian W, Li S, et al. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study. *J Int Med Res.* Jul 2018; 46(7): 2650-2657. PMID 29683022
60. Bholee AK, Peng K, Zhou Z, et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. *Clin Transl Oncol.* Jul 2017; 19(7): 844-852. PMID 28070766
61. Lan T, Chang L, Mn R, et al. Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysis. *Medicine (Baltimore).* Apr 2016; 95(15): e3185. PMID 27082558
62. Li L, Tian J, Liu P, et al. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis. *Tumori.* Jun 02 2016; 2016(3): 301-10. PMID 27002950
63. Lu Z, Wen F, Guo Q, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. *Eur J Gastroenterol Hepatol.* Feb 2013; 25(2): 187-94. PMID 23134976



64. Wang X, Hu Y, Ren M, et al. Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis. *Korean J Radiol.* 2016; 17(1): 93-102. PMID 26798221
65. Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. *Radiology.* Feb 2012; 262(2): 689-700. PMID 22157201
66. Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. *Cancer.* Dec 01 2010; 116(23): 5452-60. PMID 20672352
67. Shibata T, Isoda H, Hirokawa Y, et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. *Radiology.* Sep 2009; 252(3): 905-13. PMID 19567647
68. Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. *JAMA.* Apr 09 2008; 299(14): 1669-77. PMID 18398079
69. DeAngelis CD, Fontanarosa PB. Retraction: Cheng B-Q, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. *JAMA.* 2008;299(14):1669-1677. *JAMA.* May 13 2009; 301(18): 1931. PMID 19380477
70. Yi Y, Zhang Y, Wei Q, et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. *Chin J Cancer Res.* Feb 2014; 26(1): 112-8. PMID 24653633
71. Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol.* Feb 01 2013; 31(4): 426-32. PMID 23269991
72. Martin AP, Bartels M, Hauss J, et al. Overview of the MELD score and the UNOS adult liver allocation system. *Transplant Proc.* Dec 2007; 39(10): 3169-74. PMID 18089345
73. Organ Procurement and Transplantation Network (OPTN). OPTN Policies. Updated May 2, 2024; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed August 16, 2024.
74. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med.* Mar 14 1996; 334(11): 693-9. PMID 8594428
75. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. *Liver Transpl.* Mar 2010; 16(3): 262-78. PMID 20209641
76. Butcher DA, Brandis KJ, Wang H, et al. Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: A systematic review and meta-analysis. *Eur J Surg Oncol.* Mar 2022; 48(3): 621-631. PMID 34774394
77. Si T, Chen Y, Ma D, et al. Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta-analysis. *J Gastroenterol Hepatol.* Jul 2017; 32(7): 1286-1294. PMID 28085213
78. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. *Liver Transpl.* Jun 2003; 9(6): 557-63. PMID 12783395
79. Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. *Liver Transpl.* Mar 2004; 10(3): 449-55. PMID 15004776
80. Obed A, Beham A, Püllmann K, et al. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. *World J Gastroenterol.* Feb 07 2007; 13(5): 761-7. PMID 17278200
81. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. *Am J Transplant.* Oct 2008; 8(10): 1982-9. PMID 18727702



82. Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. *Eur J Radiol.* Aug 2017; 93: 100-106. PMID 28668402
83. Park SY, Kim JH, Yoon HJ, et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. *Clin Radiol.* Apr 2011; 66(4): 322-8. PMID 21356394
84. Seidensticker R, Seidensticker M, Doegen K, et al. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. *Gastroenterol Res Pract.* 2016; 2016: 8732521. PMID 26966431
85. Lv TR, Hu HJ, Liu F, et al. The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis. *Eur J Surg Oncol.* May 2022; 48(5): 956-966. PMID 35065841
86. Edeline J, Lamarca A, McNamara MG, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. *Cancer Treat Rev.* Sep 2021; 99: 102258. PMID 34252720
87. Mosconi C, Solaini L, Vara G, et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. *Cardiovasc Intervent Radiol.* May 2021; 44(5): 728-738. PMID 33709272
88. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. *J Surg Oncol.* Feb 2015; 111(2): 213-20. PMID 25176325
89. Knüppel M, Kubicka S, Vogel A, et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. *Gastroenterol Res Pract.* 2012; 2012: 190708. PMID 21776251
90. Tai E, Kennedy S, Farrell A, et al. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. *Curr Oncol.* Dec 2020; 27(6): e537-e546. PMID 33380868
91. Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. *Semin Oncol.* Apr 2010; 37(2): 118-26. PMID 20494704
92. Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. *J Vasc Interv Radiol.* Jul 2007; 18(7): 847-55. PMID 17609443
93. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. *Cancer J.* 2003; 9(4): 261-7. PMID 12967136
94. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. *Ann Surg Oncol.* Apr 2006; 13(4): 572-81. PMID 16511671
95. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. *HPB (Oxford).* Apr 2020; 22(4): 497-505. PMID 31791894
96. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. *Eur J Radiol.* Jun 2010; 74(3): e38-44. PMID 19467811
97. Sharma KV, Gould JE, Harbour JW, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. *AJR Am J Roentgenol.* Jan 2008; 190(1): 99-104. PMID 18094299
98. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. *Cancer.* Nov 01 1995; 76(9): 1665-70. PMID 8635073
99. Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. *Melanoma Res.* Aug 2005; 15(4): 297-304. PMID 16034309
100. Sugumar K, Stitzel H, Wu V, et al. Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. *Ann Surg Oncol.* Jul 2024; 31(7): 4413-4426. PMID 38502296
101. Zacharias AJ, Jayakrishnan TT, Rajeev R, et al. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. *PLoS One.* 2015; 10(10): e0139940. PMID 26448327



102. Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. *J Vasc Interv Radiol.* Aug 2013; 24(8): 1209-17. PMID 23885916
103. Swierz MJ, Storman D, Riemsma RP, et al. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. *Cochrane Database Syst Rev.* Mar 12 2020; 3(3): CD009498. PMID 32163181
104. Hunt TM, Flowerdew AD, Birch SJ, et al. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. *Br J Surg.* Jul 1990; 77(7): 779-82. PMID 2200559
105. Eichler K, Zangos S, Mack MG, et al. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). *Int J Oncol.* Oct 2012; 41(4): 1213-20. PMID 22842404
106. Martin RC, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. *J Gastrointest Surg.* Aug 2012; 16(8): 1531-8. PMID 22528576
107. Vogl TJ, Jost A, Nour-Eldin NA, et al. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. *Br J Cancer.* Mar 27 2012; 106(7): 1274-9. PMID 22382689
108. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann Surg Oncol.* Jan 2011; 18(1): 192-8. PMID 20740319
109. Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. *Anticancer Res.* Dec 2011; 31(12): 4581-7. PMID 22199334
110. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. *Anticancer Res.* Apr 2012; 32(4): 1387-95. PMID 22493375
111. Martin RC, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. *Cancer.* Oct 15 2015; 121(20): 3649-58. PMID 26149602
112. Vogl TJ, Gruber T, Balzer JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. *Radiology.* Jan 2009; 250(1): 281-9. PMID 19092099
113. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. *Radiology.* Nov 2003; 229(2): 457-64. PMID 14500854
114. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. *J Vasc Interv Radiol.* Mar 2009; 20(3): 360-7. PMID 19167245
115. Rivera K, Jeyarajah DR, Washington K. Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review. *Front Oncol.* 2021; 11: 643383. PMID 33842354
116. Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. *Eur Radiol.* Jan 2010; 20(1): 173-80. PMID 19657653
117. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Biliary Tract Cancers, Version 2.2024. Updated April 19, 2024. https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf. Accessed August 16, 2024.
118. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology.* Dec 01 2023; 78(6): 1922-1965. PMID 37199193



119. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. *J Clin Oncol*. May 20 2024; 42(15): 1830-1850. PMID 38502889
120. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Neuroendocrine and Adrenal Tumors, Version 1.2023. Updated August 2, 2023. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed August 16, 2024.
121. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma: Uveal, Version 1.2023. Updated May 4, 2023. https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf. Accessed August 16, 2024.
122. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer, Version 2.2024. Updated April 30, 2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed August 16, 2024.
123. Chiorean EG, Nandakumar G, Fadelu T, et al. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. *JCO Glob Oncol*. Mar 2020; 6: 414-438. PMID 32150483
124. Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. *J Clin Oncol*. Jan 20 2023; 41(3): 678-700. PMID 36252154
125. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer, Version 2.2024. Updated March 11, 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed August 16, 2024.

History

Date	Comments
10/01/19	New policy, approved September 5, 2019. This policy replaces policy 8.01.505 (originally effective June 1999) which is now deleted. Policy created with literature review through May 2019. Transcatheter hepatic arterial chemoembolization may be considered medically necessary when criteria are met; considered investigational when criteria are not met.
04/01/20	Delete policy, approved March 10, 2020. This policy will be deleted effective July 2, 2020, and replaced with InterQual criteria for dates of service on or after July 2, 2020.
06/10/20	Interim Review, approved June 9, 2020, effective June 10, 2020. This policy is reinstated immediately and will no longer be deleted or replaced with InterQual criteria on July 2, 2020.
10/01/20	Annual Review approved September 1, 2020. Policy updated with literature review through June 2020; references added. Added "in combination" with radiofrequency ablation for resectable or unresectable hepatocellular carcinoma to the investigational policy statement for clarity; otherwise policy statements unchanged.
06/01/21	Update Related Policies. Corrected Renumbered Policy 8.01.431 to 8.01.43
10/01/21	Annual Review, approved September 23, 2021. Policy updated with literature review through June 3, 2021; references added. Policy statements unchanged.



Date	Comments
10/01/22	Annual Review, approved September 12, 2022. Policy updated with literature review through May 20, 2022; reference added and guidelines updated. Minor editorial refinements to policy statements; intent unchanged.
06/15/23	Update to Related Policies. 8.01.43 is replaced with 8.01.521 Radioembolization for Primary and Metastatic Tumors of the Liver.
10/01/23	Annual Review, approved September 11, 2023. Changed the wording from "patient" to "individual" throughout the policy for standardization. Policy updated with literature review through May 23, 2023; reference added and guidelines updated. Policy statements unchanged.
10/01/24	Annual Review, approved September 23, 2024. Policy updated with literature review through May 21, 2024; references added. Minor editorial refinements to policy statements to specify intrahepatic cholangiocarcinoma.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2024 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

